高级检索
当前位置: 首页 > 详情页

Discovery of a novel small-molecule inhibitor of Fam20C that induces apoptosis and inhibits migration in triple negative breast cancer.

文献详情

资源类型:
Pubmed体系:
机构: [1]School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031, China. [2]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China. [3]Key Laboratory of Structure-Based Drug Design &amp Discovery of Ministry of Education, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, China. [4]The Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, 518107, China.
出处:
ISSN:

关键词: Triple negative breast cancer (TNBC) Fam20C Small-molecule inhibitor Apoptosis Migration

摘要:
The family with sequence similarity 20, member C (Fam20C), a Golgi casein kinase, has been recently regarded as a potential therapeutic target for the treatment of triple negative breast cancer (TNBC). Lacking enzyme activity center has been becoming an obstacle to the development of small-molecule inhibitors of Fam20C. Herein, we combined in silico high-throughput screening with chemical synthesis methods to obtain a new small-molecule Fam20C inhibitor 3r, which exhibited desired anti-proliferative activities against MDA-MB-231 cells and also inhibited migration. Subsequently, the enzymatic assay, molecular docking, and molecular dynamics (MD) simulations were carried out for validating that 3r could bind to Fam20C. In addition, 3r was found to induce apoptosis via the mitochondrial pathway in MDA-MB-231 cells as well as to inhibit cell migration. Moreover, we demonstrated that 3r inhibited tumor growth in vivo and thereby having a good therapeutic potential on TNBC. Taken together, these results suggest that 3r may be a novel Fam20C inhibitor with anti-proliferative and apoptosis-inducing activities, which would shed light on discovering more small-molecule drugs for the future TNBC therapy. Copyright © 2020 Elsevier Masson SAS. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 1 区 医学
小类 | 1 区 药物化学
最新[2023]版:
大类 | 2 区 医学
小类 | 1 区 药物化学
第一作者:
第一作者机构: [1]School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号